Status epilepticus is a rare and dangerous condition where seizures go on for too long or happen one after another without stopping. It has been estimated that up to 150,000 cases of status epilepticus occur annually in the U.S.
The company we are profiling today is Marinus Pharmaceuticals Inc. (MRNS), which is investigating the potential of its lead drug candidate IV Ganaxolone for patients with status epilepticus.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com